Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) EBIT Margin (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed EBIT Margin for 6 consecutive years, with 866.28% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin changed N/A to 866.28% in Q4 2025 year-over-year; TTM through Dec 2025 was 1971.59%, a 175048.0% increase, with the full-year FY2025 number at 1971.59%, up 175048.0% from a year prior.
  • EBIT Margin was 866.28% for Q4 2025 at Relay Therapeutics, up from 11351.11% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 9219600.0% in Q4 2023 to a low of 89117.65% in Q2 2023.
  • A 5-year average of 558290.84% and a median of 11647.6% in 2021 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: tumbled -74129766bps in 2021, then surged 924839486bps in 2023.
  • Relay Therapeutics' EBIT Margin stood at 11944.09% in 2021, then tumbled by -141bps to 28794.86% in 2022, then skyrocketed by 32118bps to 9219600.0% in 2023, then plummeted by -100bps to 903.0% in 2024, then rose by 4bps to 866.28% in 2025.
  • Per Business Quant, the three most recent readings for RLAY's EBIT Margin are 866.28% (Q4 2025), 11351.11% (Q2 2025), and 1105.21% (Q1 2025).